Matthew M. Cousins
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Matthew M. Cousins has a total of 134 co-authors. Here are the top co-authors by number of shared publications:
- Susan H. Eshleman
Department of Pathology, Johns Hopkins University School of Medicine , Baltimore, Maryland
8 shared publications - Oliver Laeyendecker
Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
6 shared publications Thomas C. Quinn
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America
6 shared publicationsConnie Celum
Departments of Global Health and Medicine, University of Washington, Seattle, Washington, United States of America
5 shared publications- Deborah Donnell
Fred Hutchinson Cancer Center
5 shared publications George R. Seage
Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, United States of America
5 shared publications
Latest Publications
- 30 November 2022
- Published by Elsevier in Practical Radiation Oncology
- Vol. 13 (2) , 112-121
Cannabis Use in Patients Seen in an Academic Radiation Oncology Department
- 30 November 2022
- Published by Elsevier in Practical Radiation Oncology
- Vol. 13 (2) , 112-121
Cannabis Use in Patients Seen in an Academic Radiation Oncology Department
- Open Access
- 17 November 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (11) , e0277617
Age, race, insurance type, and digital divide index are associated with video visit completion for patients seen for oncologic care in a large hospital system during the COVID-19 pandemic
Introduction: The COVID-19 pandemic drove rapid adoption of telehealth across oncologic specialties. This revealed barriers to telehealth access and telehealth-related disparities. We explored disparities in telehealth access in patients with cancer accessing oncologic care. Materials/Methods: Data for all unique patient visits at a large academic medical center were acquired pre- and intra-pandemic (7/1/2019-12/31/2020), including visit type (in-person, video, audio only), age, race, ethnicity, rural/urban (per zip code by Federal Office of Rural Health Policy), distance from medical facility, insurance, and Digital Divide Index (DDI; incorporates technology/internet access, age, disability, and educational attainment metrics by geographic area). Pandemic phases were identified based on visit dynamics. Multivariable logistic regression models were used to examine associations of these variables with successful video visit completion. Results: Data were available for 2,398,633 visits for 516,428 patients across all specialties. Among these, there were 253,880 visits from 62,172 patients seen in any oncology clinic. Dramatic increases in telehealth usage were seen during the pandemic (after 3/16/2020). In multivariable analyses, patient age [OR: 0.964, (95% CI 0.961, 0.966) P<0.0001], rural zip code [OR: 0.814 (95% CI 0.733, 0.904) P = 0.0001], Medicaid enrollment [OR: 0.464 (95% CI 0.410, 0.525) P<0.0001], Medicare enrollment [OR: 0.822 (95% CI 0.761, 0.888) P = 0.0053], higher DDI [OR: 0.903 (95% CI 0.877, 0.930) P<0.0001], distance from the facility [OR: 1.028 (95% CI 1.021, 1.035) P<0.0001], black race [OR: 0.663 (95% CI 0.584, 0.753) P<0.0001], and Asian race [OR: 1.229 (95% CI 1.022, 1.479) P<0.0001] were associated with video visit completion early in the pandemic. Factors related to video visit completion later in the pandemic and within sub-specialties of oncology were also explored. Conclusions: Patients from older age groups, those with minority backgrounds, and individuals from areas with less access to technology (high DDI) as well as those with Medicare or Medicaid insurance were less likely to use video visits. With greater experience through the pandemic, disparities were not mitigated. Further efforts are required to optimize telehealth to benefit all patients and avoid increasing disparities in care delivery.
- 17 November 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (11) , e0277617
Open AccessAge, race, insurance type, and digital divide index are associated with video visit completion for patients seen for oncologic care in a large hospital system during the COVID-19 pandemic
Introduction: The COVID-19 pandemic drove rapid adoption of telehealth across oncologic specialties. This revealed barriers to telehealth access and telehealth-related disparities. We explored disparities in telehealth access in patients with cancer accessing oncologic care. Materials/Methods: Data for all unique patient visits at a large academic medical center were acquired pre- and intra-pandemic (7/1/2019-12/31/2020), including visit type (in-person, video, audio only), age, race, ethnicity, rural/urban (per zip code by Federal Office of Rural Health Policy), distance from medical facility, insurance, and Digital Divide Index (DDI; incorporates technology/internet access, age, disability, and educational attainment metrics by geographic area). Pandemic phases were identified based on visit dynamics. Multivariable logistic regression models were used to examine associations of these variables with successful video visit completion. Results: Data were available for 2,398,633 visits for 516,428 patients across all specialties. Among these, there were 253,880 visits from 62,172 patients seen in any oncology clinic. Dramatic increases in telehealth usage were seen during the pandemic (after 3/16/2020). In multivariable analyses, patient age [OR: 0.964, (95% CI 0.961, 0.966) P<0.0001], rural zip code [OR: 0.814 (95% CI 0.733, 0.904) P = 0.0001], Medicaid enrollment [OR: 0.464 (95% CI 0.410, 0.525) P<0.0001], Medicare enrollment [OR: 0.822 (95% CI 0.761, 0.888) P = 0.0053], higher DDI [OR: 0.903 (95% CI 0.877, 0.930) P<0.0001], distance from the facility [OR: 1.028 (95% CI 1.021, 1.035) P<0.0001], black race [OR: 0.663 (95% CI 0.584, 0.753) P<0.0001], and Asian race [OR: 1.229 (95% CI 1.022, 1.479) P<0.0001] were associated with video visit completion early in the pandemic. Factors related to video visit completion later in the pandemic and within sub-specialties of oncology were also explored. Conclusions: Patients from older age groups, those with minority backgrounds, and individuals from areas with less access to technology (high DDI) as well as those with Medicare or Medicaid insurance were less likely to use video visits. With greater experience through the pandemic, disparities were not mitigated. Further efforts are required to optimize telehealth to benefit all patients and avoid increasing disparities in care delivery.
- 3 February 2022
- Published by Elsevier in Brachytherapy
- Vol. 21 (3) , 300-307
Rectal sparing in prostate radiotherapy with combination-brachytherapy and hydrogel spacer
- 3 February 2022
- Published by Elsevier in Brachytherapy
- Vol. 21 (3) , 300-307
Rectal sparing in prostate radiotherapy with combination-brachytherapy and hydrogel spacer
- 24 September 2021
- Published by Springer Nature in Evidence-Based Dentistry
- Vol. 22 (3) , 118-119
Can removal of amalgam restorations reduce health complaints in patients with medically unexplained physical symptoms?
Design Three groups of non-equivalent patients using a prospective cohort study design. Patients who credited their medically unexplained symptoms (MUPS) to their dental amalgam restorations (amalgam cohort) were compared to two other groups: patients with MUPS who did not credit their symptoms to amalgam (MUPS cohort) and those who recognised themselves as healthy (healthy cohort). All participants initially filled in a questionnaire (Q1) which included the primary outcome: General Health Complaints index (GHC-index). The SF-36 Physical and Mental Component Summary was also included as a secondary outcome. Other outcomes, including blood, were collected but results will be reported in other publications. Patients in the amalgam and MUPS cohorts were assessed by their general physician (GP) to ensure their complaints met the criteria for MUPS. The amalgam cohort then had their amalgams removed by their dentist and, one year later, filled in the questionnaire again (Q2). The MUPS and healthy cohorts completed the Q2 two years after the Q1. Cohort selection Recruitment information for the amalgam cohort was sent to all dentists and GPs in Norway, and advertised via the Directorate of Health website and the Norwegian Dental Association. Once potential participants were identified, they were required to be assessed by both a dentist and GP to declare that oral and systemic diseases were adequately treated. The risk of deterioration of dental and medical health through participation in the study was also disclosed. For the amalgam cohort, patients had to have at least one amalgam filling and attribute the presence of these restorations to unexplained health complaints which had been present for at least three months. Patients in the MUPS cohort were recruited by their GP. These patients also had to have had unexplained health complaints for at least three months; however, the key difference being they did not attribute these complaints to amalgams. The healthy cohort was primarily recruited via dentists taking part in the study and patients self-assessed as being healthy. Both the MUPS and healthy cohorts were recruited regardless of amalgam status. Data analysis Descriptive statistics presented continuous data, and categorical data were presented as frequencies. Differences between the cohorts were analysed with analysis of variance (ANOVA) with covariate adjustment. Potential predictors of the primary outcome variable were analysed using multivariate analysis. Results In the amalgam, MUPS and healthy cohorts, 32, 28 and 19 patients, respectively, completed participation in the study. The GHC-index significantly reduced (p <0.001) between Q1 and Q2 in the amalgam cohort but not in the other cohorts. The change in the GHC-index (change in score) was greater in the amalgam cohort compared to the MUPS cohort and this was statistically significant (p = 0.004), indicating a greater reduction in health complaints. Conclusions General health complaints in patients with MUPS, that attributed their symptoms to their dental amalgams, reduced after removal of dental amalgam restorations.
- 24 September 2021
- Published by Springer Nature in Evidence-Based Dentistry
- Vol. 22 (3) , 118-119
Can removal of amalgam restorations reduce health complaints in patients with medically unexplained physical symptoms?
Design Three groups of non-equivalent patients using a prospective cohort study design. Patients who credited their medically unexplained symptoms (MUPS) to their dental amalgam restorations (amalgam cohort) were compared to two other groups: patients with MUPS who did not credit their symptoms to amalgam (MUPS cohort) and those who recognised themselves as healthy (healthy cohort). All participants initially filled in a questionnaire (Q1) which included the primary outcome: General Health Complaints index (GHC-index). The SF-36 Physical and Mental Component Summary was also included as a secondary outcome. Other outcomes, including blood, were collected but results will be reported in other publications. Patients in the amalgam and MUPS cohorts were assessed by their general physician (GP) to ensure their complaints met the criteria for MUPS. The amalgam cohort then had their amalgams removed by their dentist and, one year later, filled in the questionnaire again (Q2). The MUPS and healthy cohorts completed the Q2 two years after the Q1. Cohort selection Recruitment information for the amalgam cohort was sent to all dentists and GPs in Norway, and advertised via the Directorate of Health website and the Norwegian Dental Association. Once potential participants were identified, they were required to be assessed by both a dentist and GP to declare that oral and systemic diseases were adequately treated. The risk of deterioration of dental and medical health through participation in the study was also disclosed. For the amalgam cohort, patients had to have at least one amalgam filling and attribute the presence of these restorations to unexplained health complaints which had been present for at least three months. Patients in the MUPS cohort were recruited by their GP. These patients also had to have had unexplained health complaints for at least three months; however, the key difference being they did not attribute these complaints to amalgams. The healthy cohort was primarily recruited via dentists taking part in the study and patients self-assessed as being healthy. Both the MUPS and healthy cohorts were recruited regardless of amalgam status. Data analysis Descriptive statistics presented continuous data, and categorical data were presented as frequencies. Differences between the cohorts were analysed with analysis of variance (ANOVA) with covariate adjustment. Potential predictors of the primary outcome variable were analysed using multivariate analysis. Results In the amalgam, MUPS and healthy cohorts, 32, 28 and 19 patients, respectively, completed participation in the study. The GHC-index significantly reduced (p <0.001) between Q1 and Q2 in the amalgam cohort but not in the other cohorts. The change in the GHC-index (change in score) was greater in the amalgam cohort compared to the MUPS cohort and this was statistically significant (p = 0.004), indicating a greater reduction in health complaints. Conclusions General health complaints in patients with MUPS, that attributed their symptoms to their dental amalgams, reduced after removal of dental amalgam restorations.
Prevalence of cannabis use among individuals with a history of cancer in the United States
Background: Patients with cancer have played a key role in advocating for legal access to cannabis, but little is known about links between cancer and cannabis use or cannabis‐related beliefs. The authors used data from a national survey to study these relationships.Methods: Nationally representative data collected by the National Survey on Drug Use and Health from 2015 to 2019 were acquired. Patterns of cannabis use and cancer history were examined and tested within age group subpopulations via domain analysis using survey weights.Results: Data for 214,505 adults, including 4741 individuals (3.8%) with past (>1 year ago) cancer diagnosis and 1518 individuals (1.2%) with recent (≤1 year ago) cancer diagnosis, were examined. Cannabis use was less common in those with past (8.9%; 95% CI, 8.0%‐9.8%) or recent (9.9%; 95% CI, 6.9%‐11.1%) cancer diagnosis than in those without a history of cancer (15.9%; 95% CI, 15.7%‐16.1%). However, when analyses were stratified by age group, those 18 to 34 years of age were more likely to report past cannabis use, and those 35 to 49 years of age were more likely to report past or recent cannabis use if they had a history of cancer. Younger patients felt that cannabis was more accessible and less risky if they had a history of cancer.Conclusions: Patients with cancer were less likely to report cannabis use, but there were different cannabis perceptions and use patterns by age. Age should be considered in studies of cannabis and cancer, and policy initiatives may be needed to aid provision of quality information on cannabis risk to those with cancer.Lay Summary: Cannabis (marijuana) use is increasing in the United States, but we do not have much information on the relationship between cannabis use and cancer. We studied information from a representative group of people and found that younger patients generally reported more past and/or recent cannabis use if they had been diagnosed with cancer whereas older individuals did not. Beliefs about cannabis risk and accessibility differed by age. Clinical trials to study cannabis should account for patient age, and accurate information about cannabis should be provided to help patients with cancer make decisions about cannabis use.
Prevalence of cannabis use among individuals with a history of cancer in the United States
Background: Patients with cancer have played a key role in advocating for legal access to cannabis, but little is known about links between cancer and cannabis use or cannabis‐related beliefs. The authors used data from a national survey to study these relationships.Methods: Nationally representative data collected by the National Survey on Drug Use and Health from 2015 to 2019 were acquired. Patterns of cannabis use and cancer history were examined and tested within age group subpopulations via domain analysis using survey weights.Results: Data for 214,505 adults, including 4741 individuals (3.8%) with past (>1 year ago) cancer diagnosis and 1518 individuals (1.2%) with recent (≤1 year ago) cancer diagnosis, were examined. Cannabis use was less common in those with past (8.9%; 95% CI, 8.0%‐9.8%) or recent (9.9%; 95% CI, 6.9%‐11.1%) cancer diagnosis than in those without a history of cancer (15.9%; 95% CI, 15.7%‐16.1%). However, when analyses were stratified by age group, those 18 to 34 years of age were more likely to report past cannabis use, and those 35 to 49 years of age were more likely to report past or recent cannabis use if they had a history of cancer. Younger patients felt that cannabis was more accessible and less risky if they had a history of cancer.Conclusions: Patients with cancer were less likely to report cannabis use, but there were different cannabis perceptions and use patterns by age. Age should be considered in studies of cannabis and cancer, and policy initiatives may be needed to aid provision of quality information on cannabis risk to those with cancer.Lay Summary: Cannabis (marijuana) use is increasing in the United States, but we do not have much information on the relationship between cannabis use and cancer. We studied information from a representative group of people and found that younger patients generally reported more past and/or recent cannabis use if they had been diagnosed with cancer whereas older individuals did not. Beliefs about cannabis risk and accessibility differed by age. Clinical trials to study cannabis should account for patient age, and accurate information about cannabis should be provided to help patients with cancer make decisions about cannabis use.
- Open Access
- 16 March 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (3) , e0248227
Differences between cancer patients and others who use medicinal Cannabis
Background: Cancer patients have been at the forefront of policy discussions leading to legalization of medical Cannabis (marijuana). Unfortunately, Cannabis use among those with cancer is poorly understood. Methods: A diverse group of patients seeking certification for medical Cannabis in the state of Michigan were surveyed at the time of their presentation to medical dispensaries. The survey assessed demographics, employment/disability, pain, physical functioning, mental health, mode of Cannabis use, and frequency/amount of Cannabis use. Chi-square and t-tests were performed to compare those who did and did not endorse cancer diagnosis. Results: Analysis of data from 1485 adults pursuing medical Cannabis certification, including 72 (4.8%) reporting a cancer diagnosis, indicated that those with cancer were older [mean age 53.4 years (SD = 10.5) vs. 44.7 years (SD = 13.0); p<0.001] than those without cancer. They also differed regarding employment status (p<0.001; working: 20.8% vs. 46.2%; disabled: 44.4% vs. 26.5% for those with vs. those without cancer, respectively). Those with cancer used less Cannabis (p = 0.033 for quantity used) and used Cannabis less often (p = 0.032 for frequency of use); they less frequently endorsed smoking Cannabis (80% vs 91%; p = 0.015). There was a non-significant trend to increased edible use in those with cancer (57% vs. 44%; p = 0.052). Conclusions: Patients with cancer who are seeking medical Cannabis are different from those seeking medical Cannabis without cancer, and they report using Cannabis differently. Further research to characterize the patterns and consequences of Cannabis use in cancer patients is needed.
- 16 March 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (3) , e0248227
Open AccessDifferences between cancer patients and others who use medicinal Cannabis
Background: Cancer patients have been at the forefront of policy discussions leading to legalization of medical Cannabis (marijuana). Unfortunately, Cannabis use among those with cancer is poorly understood. Methods: A diverse group of patients seeking certification for medical Cannabis in the state of Michigan were surveyed at the time of their presentation to medical dispensaries. The survey assessed demographics, employment/disability, pain, physical functioning, mental health, mode of Cannabis use, and frequency/amount of Cannabis use. Chi-square and t-tests were performed to compare those who did and did not endorse cancer diagnosis. Results: Analysis of data from 1485 adults pursuing medical Cannabis certification, including 72 (4.8%) reporting a cancer diagnosis, indicated that those with cancer were older [mean age 53.4 years (SD = 10.5) vs. 44.7 years (SD = 13.0); p<0.001] than those without cancer. They also differed regarding employment status (p<0.001; working: 20.8% vs. 46.2%; disabled: 44.4% vs. 26.5% for those with vs. those without cancer, respectively). Those with cancer used less Cannabis (p = 0.033 for quantity used) and used Cannabis less often (p = 0.032 for frequency of use); they less frequently endorsed smoking Cannabis (80% vs 91%; p = 0.015). There was a non-significant trend to increased edible use in those with cancer (57% vs. 44%; p = 0.052). Conclusions: Patients with cancer who are seeking medical Cannabis are different from those seeking medical Cannabis without cancer, and they report using Cannabis differently. Further research to characterize the patterns and consequences of Cannabis use in cancer patients is needed.
- 1 January 2021
- Published by Elsevier in Medical Dosimetry
- Vol. 46 (4) , 404-410
Prostate radiotherapy in the setting of bilateral hip prostheses: All commonly used photon-based radiation approaches are feasible
- 1 January 2021
- Published by Elsevier in Medical Dosimetry
- Vol. 46 (4) , 404-410
Prostate radiotherapy in the setting of bilateral hip prostheses: All commonly used photon-based radiation approaches are feasible
- Open Access
- 1 January 2021
- Published by Elsevier in Translational Oncology
- Vol. 14 (1)
TNFR1 and the TNFα axis as a targetable mediator of liver injury from stereotactic body radiation therapy
- 1 January 2021
- Published by Elsevier in Translational Oncology
- Vol. 14 (1)
Open AccessTNFR1 and the TNFα axis as a targetable mediator of liver injury from stereotactic body radiation therapy
- 1 December 2017
- Published by Horticultural Research Institute in Journal of Environmental Horticulture
- Vol. 35 (4) , 128-137
Beach Vitex (Vitex rotundifolia): Medicinal Properties, Biology, Invasive Characteristics and Management Options1
Beach Vitex (BV) (Vitex rotundifolia-L. f.) has become a major invasive plant in the fragile beach ecosystems of the Carolinas. This prostrate, salt tolerant shrub from the Pacific Rim was introduced to the southeastern United States as a landscape plant. It has since established large-scale clonal monocultures through rapid vegetative reproduction. Concerns surrounding exclusion of native species and inhibition of sea turtle nesting have served as the impetus for control efforts of BV in coastal areas of southeastern US. In areas where it occurs naturally, native peoples have included BV in their pharmacopias for treatment of many ailments. The purpose of this review is to raise awareness of its invasive potential while serving as a compilation of information about the biology, ecology and medicinal properties of BV. Its potential beneficial uses indicate a need for further exploration and development of this plant but only in areas away from the coast. This plant is a major invasive problem in coastal areas for many reasons and must be dealt with quickly so that it will not become a larger problem. Imazapyr effectively controlled beach vitex in reported greenhouse and field studies applied either as a cut stem treatment or as a foliar spray.Index words: Carolina beaches, Coastal landscape plants, Herbicides, Invasive plants.
- 1 December 2017
- Published by Horticultural Research Institute in Journal of Environmental Horticulture
- Vol. 35 (4) , 128-137
Beach Vitex (Vitex rotundifolia): Medicinal Properties, Biology, Invasive Characteristics and Management Options1
Beach Vitex (BV) (Vitex rotundifolia-L. f.) has become a major invasive plant in the fragile beach ecosystems of the Carolinas. This prostrate, salt tolerant shrub from the Pacific Rim was introduced to the southeastern United States as a landscape plant. It has since established large-scale clonal monocultures through rapid vegetative reproduction. Concerns surrounding exclusion of native species and inhibition of sea turtle nesting have served as the impetus for control efforts of BV in coastal areas of southeastern US. In areas where it occurs naturally, native peoples have included BV in their pharmacopias for treatment of many ailments. The purpose of this review is to raise awareness of its invasive potential while serving as a compilation of information about the biology, ecology and medicinal properties of BV. Its potential beneficial uses indicate a need for further exploration and development of this plant but only in areas away from the coast. This plant is a major invasive problem in coastal areas for many reasons and must be dealt with quickly so that it will not become a larger problem. Imazapyr effectively controlled beach vitex in reported greenhouse and field studies applied either as a cut stem treatment or as a foliar spray.Index words: Carolina beaches, Coastal landscape plants, Herbicides, Invasive plants.
- Open Access
- 26 June 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (6) , e101043
A Comparison of Two Measures of HIV Diversity in Multi-Assay Algorithms for HIV Incidence Estimation
Multi-assay algorithms (MAAs) can be used to estimate HIV incidence in cross-sectional surveys. We compared the performance of two MAAs that use HIV diversity as one of four biomarkers for analysis of HIV incidence. Both MAAs included two serologic assays (LAg-Avidity assay and BioRad-Avidity assay), HIV viral load, and an HIV diversity assay. HIV diversity was quantified using either a high resolution melting (HRM) diversity assay that does not require HIV sequencing (HRM score for a 239 base pair env region) or sequence ambiguity (the percentage of ambiguous bases in a 1,302 base pair pol region). Samples were classified as MAA positive (likely from individuals with recent HIV infection) if they met the criteria for all of the assays in the MAA. The following performance characteristics were assessed: (1) the proportion of samples classified as MAA positive as a function of duration of infection, (2) the mean window period, (3) the shadow (the time period before sample collection that is being assessed by the MAA), and (4) the accuracy of cross-sectional incidence estimates for three cohort studies. The proportion of samples classified as MAA positive as a function of duration of infection was nearly identical for the two MAAs. The mean window period was 141 days for the HRM-based MAA and 131 days for the sequence ambiguity-based MAA. The shadows for both MAAs were <1 year. Both MAAs provided cross-sectional HIV incidence estimates that were very similar to longitudinal incidence estimates based on HIV seroconversion. MAAs that include the LAg-Avidity assay, the BioRad-Avidity assay, HIV viral load, and HIV diversity can provide accurate HIV incidence estimates. Sequence ambiguity measures obtained using a commercially-available HIV genotyping system can be used as an alternative to HRM scores in MAAs for cross-sectional HIV incidence estimation.
- 26 June 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (6) , e101043
Open AccessA Comparison of Two Measures of HIV Diversity in Multi-Assay Algorithms for HIV Incidence Estimation
Multi-assay algorithms (MAAs) can be used to estimate HIV incidence in cross-sectional surveys. We compared the performance of two MAAs that use HIV diversity as one of four biomarkers for analysis of HIV incidence. Both MAAs included two serologic assays (LAg-Avidity assay and BioRad-Avidity assay), HIV viral load, and an HIV diversity assay. HIV diversity was quantified using either a high resolution melting (HRM) diversity assay that does not require HIV sequencing (HRM score for a 239 base pair env region) or sequence ambiguity (the percentage of ambiguous bases in a 1,302 base pair pol region). Samples were classified as MAA positive (likely from individuals with recent HIV infection) if they met the criteria for all of the assays in the MAA. The following performance characteristics were assessed: (1) the proportion of samples classified as MAA positive as a function of duration of infection, (2) the mean window period, (3) the shadow (the time period before sample collection that is being assessed by the MAA), and (4) the accuracy of cross-sectional incidence estimates for three cohort studies. The proportion of samples classified as MAA positive as a function of duration of infection was nearly identical for the two MAAs. The mean window period was 141 days for the HRM-based MAA and 131 days for the sequence ambiguity-based MAA. The shadows for both MAAs were <1 year. Both MAAs provided cross-sectional HIV incidence estimates that were very similar to longitudinal incidence estimates based on HIV seroconversion. MAAs that include the LAg-Avidity assay, the BioRad-Avidity assay, HIV viral load, and HIV diversity can provide accurate HIV incidence estimates. Sequence ambiguity measures obtained using a commercially-available HIV genotyping system can be used as an alternative to HRM scores in MAAs for cross-sectional HIV incidence estimation.